Exploring the Potential Drug Target TBC1D24 (DEE16) and its Connection to Human Health

Target Name: TBC1D24

NCBI ID: G57465

TBC1D24

Exploring the Potential Drug Target TBC1D24 (DEE16) and its Connection to Human Health

The protein TBC1D24 (DEE16) has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This protein plays a crucial role in the regulation of cell growth, differentiation, and survival, and its dysfunction has been implicated in numerous human diseases. In this article, we will explore the potential drug target TBC1D24 (DEE16) and its connection to human health.

Potential Drug Target: TBC1D24 (DEE16)

TBC1D24 (DEE16) is a non-coding RNA molecule that is expressed in various tissues and cell types. It is a key regulator of the T-cell receptor (TCR), which is responsible for cell survival and division. TBC1D24 (DEE16) has been shown to play a crucial role in the regulation of TCR-driven cell growth, differentiation, and survival.

One of the most significant functions of TBC1D24 (DEE16) is its role in the regulation of the TCR. The TCR is a transmembrane protein that is involved in the recognition of foreign antigens and in the regulation of cellular immunity. TBC1D24 (DEE16) is known to be a negative regulator of the TCR, which means that it works to prevent the activation and proliferation of T cells.

In addition to its role in the regulation of the TCR, TBC1D24 (DEE16) has also been shown to play a role in the regulation of cell growth, differentiation, and survival. It has been shown to promote the growth and differentiation of various cell types, including T cells, and it has been implicated in the regulation of cell survival and apoptosis.

Potential Applications of TBC1D24 (DEE16) as a Drug Target

The potential applications of TBC1D24 (DEE16) as a drug target are vast and varied. One of the most promising applications is its use as a target for cancer therapy. TBC1D24 (DEE16) has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Therefore, targeting TBC1D24 (DEE16) with small molecules or antibodies has the potential to be an effective cancer therapeutic.

Another promising application of TBC1D24 (DEE16) as a drug target is its role in the treatment of neurodegenerative disorders. TBC1D24 (DEE16) has been shown to be involved in the regulation of neural stem cell survival and proliferation, as well as the regulation of neurotransmitter release. Therefore, targeting TBC1D24 (DEE16) with small molecules or antibodies has the potential to be an effective neurodegenerative disorder therapeutic.

In addition to its potential applications in cancer and neurodegenerative disorders, TBC1D24 (DEE16) has also been shown to be involved in the regulation of autoimmune diseases. TBC1D24 (DEE16) has been shown to be involved in the regulation of immune cell function and has been implicated in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Therefore, targeting TBC1D24 (DEE16) with small molecules or antibodies has the potential to be an effective autoimmune disease therapeutic.

Current Research on TBC1D24 (DEE16)

While the potential applications of TBC1D24 (DEE16) as a drug target are vast, current research on TBC1D24 (DEE16) is limited. There are currently no approved drugs that

Protein Name: TBC1 Domain Family Member 24

Functions: May act as a GTPase-activating protein for Rab family protein(s) (PubMed:20727515, PubMed:20797691). Involved in neuronal projections development, probably through a negative modulation of ARF6 function (PubMed:20727515). Involved in the regulation of synaptic vesicle trafficking (PubMed:31257402)

The "TBC1D24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets